Evidence map›Paper›PMID 41103964›Full record

ArticleFrontiers in oncology2025

Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals.

Catherine S Y Lecat, Sotirios Bristogiannis, Dipal Mehta, Yadanar Lwin, Joanne Land, Orla McCourt, Emma Dowling, Nuno Correia, Neil K Rabin, Ke Xu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Catherine S Y LecatDepartment of Haematology, University College London (UCL) Cancer Institute, London, United Kingdom.
Sotirios BristogiannisDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Dipal MehtaDepartment of Haematology, University College London (UCL) Cancer Institute, London, United Kingdom.
Yadanar LwinDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Joanne LandDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Orla McCourtDepartment of Haematology, University College London (UCL) Cancer Institute, London, United Kingdom.
Emma DowlingDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Nuno CorreiaDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Neil K RabinDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Ke XuDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Jonathan SiveDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Xenofon PapanikolaouDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Rakesh PopatDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Lydia LeeDepartment of Haematology, University College London (UCL) Cancer Institute, London, United Kingdom.
Annabel McMillanDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
Eileen M BoyleDepartment of Haematology, University College London (UCL) Cancer Institute, London, United Kingdom.
Kwee YongDepartment of Haematology, University College London (UCL) Cancer Institute, London, United Kingdom.
Charalampia KyriakouDepartment of Haematology, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As multiple myeloma (MM) patients live longer, maintaining quality of life (QOL) has become an important treatment goal. However, the commonly used general quality of life questionnaires (QOLQs) were developed over 20 years ago. In this survey, 224 MM patients and 48 healthcare professionals (HCPs) were asked to grade the relevance and importance of QOL items from 9 validated, frequently used MM QOLQs. The results from this survey highlighted significant discrepancy between MM patients' and HCPs' perception of important and relevant QOL issues. Whilst MM HCPs found all QOL items relevant, the patients reported a proportion of these items being relevant. These were mainly related to physical functioning, social/family wellbeing, pain and fatigue. This real-world survey stressed the need for the development of an updated QOLQ that is relevant to patients and current MM therapies.

Indexed as

healthcare professional (HCP)health related qualitiy of lifemutliple myelomamyelomaPROM (patient reported outcome measurement)quality of life

Identifiers

PMID41103964
PMCPMC12520875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.